Non–High-Density Lipoprotein Cholesterol as a Biomarker for Nonalcoholic Steatohepatitis
- 30 June 2012
- journal article
- research article
- Published by Elsevier BV in Clinical Gastroenterology and Hepatology
- Vol. 10 (6), 651-656
- https://doi.org/10.1016/j.cgh.2012.01.017
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Atorvastatin and Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease: The St Francis Heart Study Randomized Clinical TrialAmerican Journal Of Gastroenterology, 2011
- Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver DiseaseClinical Gastroenterology and Hepatology, 2009
- Serum adipokine levels predictive of liver injury in non‐alcoholic fatty liver diseaseLiver International, 2009
- Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation studyHepatology, 2009
- Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease RiskJournal of the American College of Cardiology, 2009
- Liver biopsyHepatology, 2008
- Overproduction of Very Low–Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic SyndromeArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Hepatic triglyceride synthesis and nonalcoholic fatty liver diseaseCurrent Opinion in Lipidology, 2008
- Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology FoundationJournal of the American College of Cardiology, 2008
- Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitisHepatology, 2007